Role of psychiatric medications as adjunct therapy in the treatment of HIV associated neurocognitive disorders

International Review of Psychiatry

Volumn 20, Issue 1, 2008, Pages 89-93

  Ances, Beau M ^a,b   Letendre, Scott L ^c   Alexander, Terry ^c   Ellis, Ronald J ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; EFAVIRENZ; ESCITALOPRAM; FLUOXETINE; LITHIUM; NEVIRAPINE; PAROXETINE; SERTRALINE; TRAZODONE; VALPROIC ACID; VENLAFAXINE;

BLOOD BRAIN BARRIER; COGNITIVE DEFECT; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DRUG INHIBITION; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOOD DISORDER; NEUROPROTECTION; PRIORITY JOURNAL; QUALITY OF LIFE; SEIZURE; SHORT SURVEY; SURVIVAL; VIRUS REPLICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAIN; CITALOPRAM; COGNITION DISORDERS; HIV INFECTIONS; HUMANS; LITHIUM CARBONATE; MENTAL DISORDERS; PAROXETINE; PSYCHOTROPIC DRUGS; SEROTONIN UPTAKE INHIBITORS; VALPROIC ACID;

EID: 38849162064     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.1080/09540260701877670     Document Type: Short Survey

References (27)

1. Ances, B. M., Letendre, S., Buzzell, M. et al. (2006). Valproic acid does not affect markers of human immunodeficiency virus disease progression. Journal of Neurovirology, 12, 403-406.
2. Atkinson, J. H., Slater, M. A., Wahlgren, D. R. et al. (1999). Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity. Pain, 83, 137-145.
3. Baldessarini, R. J., Leahy, L., Arcona, S., Gause, D., Zhang, W., & Hennen, J. (2007). Patterns of psychotropic drug prescription for US patients with diagnoses of bipolar disorders. Psychiatr Serv, 58, 85-91.
4. Cysique, L. A., Maruff, P., & Brew, B. J. (2004). Antiretroviral therapy in HIV infection: Are neurologically active drugs important? Arch Neurol, 61, 1699-1704.
5. Dewhurst, S., Maggirwar, S. B., Schifitto, G., Gendelman, H. E., & Gelbard, H. A. (2007). Glycogen synthase kinase 3 Beta (GSK-3beta) as a therapeutic target in neuroAIDS. Journal of Neuroimmune Pharmacology, 2, 93-96.
6. Dou, H., Ellison, B., Bradley, J. et al. (2005). Neuroprotective mechanisms of lithium in murine human immunodeficiency virus-1 encephalitis. Journal of Neuroscience, 25, 8375-8385.
7. Everall, I. P., Bell, C., Mallory, M. et al. (2002). Lithium ameliorates HIV-gp120-mediated neurotoxicity. Mol Cell Neurosci, 21, 493-501.
8. Gallicchio, V. S., Cibull, M. L., Hughes, N. K., & Tse, K. F. (1993). Effect of lithium in murine immunodeficiency virus infected animals. Pathobiology, 61, 216-221.
9. Harvey, B. H., Meyer, C. L., Gallichio, V. S., & Manji, H. K. (2002). Lithium salts in AIDS and AIDS-related dementia. Psychopharmacol Bull, 36, 5-26.
10. Hashimoto, M., Sagara, Y., Langford, D. et al. (2002). Fibroblast growth factor 1 regulates signaling via the glycogen synthase kinase-3beta pathway. Implications for neuroprotection. Journal of Biol Chem, 277, 32985-32991.
11. Heaton, R. K., Marcotte, T. D., Mindt, M. R. et al. (2004). The impact of HIV-associated neuropsychological impairment on everyday functioning. Journal of the International Neuropsychological Society, 10, 317-331.
12. Kandanearatchi, A., Vyakarnam, A., Landau, S., & Everall, I. P. (2004). Suppression of human immunodeficiency virus replication in human brain tissue by nucleoside reverse transcriptase inhibitors. Journal of Neurovirology, 10, 136-139.
13. Kim, A. J., Shi, Y., Austin, R. C., & Werstuck, G. H. (2005). Valproate protects cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3. Journal of Cell Science, 18, 89-99.
14. Kristiansen, J. E., & Hansen, J. B. (2000). Inhibition of HIV replication by neuroleptic agents and their potential use in HIV infected patients with AIDS related dementia. International Journal of Antimicrobial Agents, 14, 209-213.
15. Lehrman, G., Hogue, I. B., Palmer, S. et al. (2005). Depletion of latent HIV-1 infection in vivo: A proof-of-concept study. Lancet, 366, 549-555.
16. Letendre, S. L., Marquie-Beck, J., Ellis, R. J. et al. (2007). The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system. Journal of Neuroimmune Pharmacology, 2, 120-127.
17. Letendre, S. L., Woods, S. P., Ellis, R. J. et al. (2006). Lithium improves HIV-associated neurocognitive impairment. AIDS, 20, 1885-1888.
18. Maggirwar, S. B., Tong, N., Ramirez, S., Gelbard, H. A., & Dewhurst, S. (1999). HIV-1 Tat-mediated activation of glycogen synthase kinase-3beta contributes to Tat-mediated neurotoxicity. Journal of Neurochemistry, 73, 578-586.
19. Manji, H. K., McNamara, R., Chen, G., & Lenox, R. H. (1999). Signalling pathways in the brain: Xellular transduction of mood stabilisation in the treatment of manic-depressive illness. Australia & New Zealand Journal of Psychiatry, 33, S65-S83.
20. McArthur, J. C., Haughey, N., Gartner, S. et al. (2003). Human immunodeficiency virus-associated dementia: an evolving disease. Journal of Neurovirology, 9, 205-221.
21. Pieper, A. A., & Treisman, G. J. (2005). Drug treatment of depression in HIV-positive patients: Safety considerations. Drug Saf, 28, 753-762.
22. Sacktor, N., McDermott, M. P., Marder, K. et al. (2002). HIV-associated cognitive impairment before and after the advent of combination therapy. Journal of Neurovirology, 8, 136-142.
23. Schifitto, G., Peterson, D. R., Zhong, J. et al. (2006). Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology, 66, 919-921.
24. Taylor, E. M. (2002). The impact of efflux transporters in the brain on the development of drugs for CNS disorders. Clin Pharmacokinet, 41, 81-92.
25. Tozzi, V., Balestra, P., Lorenzini, P. et al. (2005). Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: Results from an urban observational cohort. Journal of Neurovirology, 11, 265-273.
26. Wynn, H. E., Brundage, R. C., & Fletcher, C. V. (2002). Clinical implications of CNS penetration of antiretroviral drugs. CNS Drugs, 16, 595-609.
27. Yasuda, S., Liang, M. H., Marinova, Z., Yahyavi, A., & Chuang, D. M. (2007). The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Molecular Psychiatry, epub ahead of print.